Remember Me
Or use your Academic/Social account:


Or use your Academic/Social account:


You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.


Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message


Verify Password:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Macken, Lucia; Joshi, Deepak; Messenger, Jenny; Austin, Mark; Tibble, Jeremy; Mason, Louise; Verma, Sumita (2016)
Publisher: SAGE Publication
Languages: English
Types: Article
Subjects: R, R852, R1
Background: Ascites, the commonest complication of cirrhosis, leads to frequent hospitalisations. Refractory ascites (RA) confers a median survival of 6 months without liver transplantation (LT). In many the management remains palliative (large volume paracentesis, LVP). Despite calls for improvement, Palliative and End of Life (EoLC) is not yet integrated into end stage liver disease (ESLD). Long-term abdominal drains (LTAD) are a palliative strategy in malignant ascites, but not ESLD. \ud \ud Case presentation: A retrospective, single centre, case series review was performed of patients undergoing LTAD placement for RA secondary to ESLD at a large teaching hospital between August 2011 and March 2013. \ud \ud Case management: Patients with ESLD and RA, where LT was not an option, were considered for LTAD. Seven patients underwent successful LTAD insertion after multi-professional assessment.\ud \ud Case outcome: Following LTAD, mean hospital attendances reduced to 1 (0-4) from 9 (4-21); with none for ascites management. Median survival after LTAD insertion was 29 days (8-219). The complication rate was low and none life-threatening. \ud \ud Conclusions: Palliative and EoLC needs in ESLD remain under-addressed. Our data suggests LTAD may be a safe and effective palliative intervention in ESLD. Prospective randomised controlled trials comparing LVP versus LTAD in RA in ESLD are warranted.
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • 1. Potts, JR, Goubet, S, Heneghan, MA, Verma S. Determinants of long-term outcome in severe alcoholic hepatitis. Aliment Pharmacol Ther 2013; 38: 584- 595.
    • 2. EASL. Clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol 2010; 53:397-417.
    • 3. Guardiola J, Baliellas C, Xiol X, Fernandez Esparrach G, Ginès P, Ventura P, Vazquez S. External validation of a prognostic model for predicting survival of cirrhotic patients with refractory ascites. Am J Gastroenterol 2002; 97:2374- 2378.
    • 4. Veldt BJ, Lainé F, Guillygomarc'h A, Lauvin L, Boudjema K, Messner M et al. Indication of liver transplantation in severe alcoholic liver cirrhosis: quantitative evaluation and optimal timing. J Hepatol 2002; 36:93-98.
    • 5. Keen A, Fitzgerald D, Bryant A, Dickinson HO. Management of drainage for malignant ascites in gynaecological cancer. Cochrane Database Syst Rev 2010; 1:CD007794.
    • 6. Marchesini G, Bianchi G, Amodio P, Salerno F, Merli M, Panella C et al. Italian Study Group for quality of life in cirrhosis. Factors associated with poor healthrelated quality of life of patients with cirrhosis. Gastroenterol 2001; 120:170-8.
    • 7. Chen RP, Zhu Ge XJ, Huang ZM, Ye XH, Hu CY, Lu GR et al. Prophylactic use of transjugular intrahepatic portosystemic shunt aids in the treatment of refractory ascites: metaregression and trial sequential meta-analysis. J Clin Gastroenterol 2014; 48:290-299.
    • 8. Nair S, Robinson E, Fiona S, Macdonald S, Mergental H, Talbot D et al. Alfa pup fo the teatet of efacto ascites: a eal w old epeiece fo the UK. Gut 2015; 64: Suppl 1 A274-A275.
    • 9. Bellot P, Welker MW, Soriano G, von Schaewen M, Appenrodt B, Wiest R et al. Automated low flow pump system for the treatment of refractory ascites: a multi-center safety and efficacy study. J Hepatol 2013; 58:922-7.
    • 10. Rocket Medical. Indwelling Peritoneal Catheter (IPC) Insertion Kit R54400-16-40 (ZDOCK249 IFU). Rocket Medical PLC 2013.
    • 11. Williams R, Aspinall R, Bellis M, Camps-Walsh G, Cramp M, Dhawan A et al. Addressing liver disease in the UK: a blueprint for attaining excellence in health care and reducing premature mortality from lifestyle issues of excess consumption of alcohol, obesity, and viral hepatitis. Lancet. 2014; 384:1953- 1997.
    • 12. National end of life care intelligence network. Deaths from Liver Disease: Implications for end of life care in England. March 2012. (Accessed at http://www.endoflifecareintelligence.org.uk/resources/publications/deaths_from_liver_disease).
    • 13. Elizabeth Kendrick, GPwSI Older people and Chair End of Life Clinical Innovation Team, NHS North East. Getting it Right: improving end of life care for people living with liver disease. February 2013. (Accessed at http://www.yhln.org.uk/data/documents/2013/NHS%20Liver%20Care,%20Gett ing%20it%20Right%20%20Improving%20End%20of%20Life%20Care%20for%20 People%20with%20Liver%20Disease.pdf).
    • 14. White J, Carolan-Rees G. PleurX peritoneal catheter drainage system for vacuum-assisted drainage of treatment-resistant, recurrent malignant ascites: a NICE Medical Technology Guidance. Appl Health Econ Health Policy 2012; 10:299-308.
    • 15. Kriese S, Spence-Adams S, Al-Khadimi G, Suddle AR, Agarwal KA, Peddu P. Palliative Management of Symptomatic Refractory Ascites Secondary to Liver Cirrhosis with Tunnelled Peritoneal Drainage Catheters. A Report of Preliminary Experience. In: EAPC 2013. 13th World Congress of the European Association for Palliative Care, Prague, Czech Republic 30 May - 2 June 2013, poster number P1-395. Prague: EPAC.
    • 16. Kundu S, Bettmann M. The Safety and Efficacy of Tunneled, Indwelling Peritoneal Catheter Drainage for Refractory, Non-Malignant Ascites. Am J Gastroenterol Suppl 2012; 107:S1-S880.
    • 17. Imler T, Abd El-Jawad K, Kwo P, Vuppalanchi R, Chalasani N. To Drain or Not Drain: PleurX Indwelling Drainage Catheters for Non-Malignant Refractory Ascites or Hepatic Hydrothorax. Am J Gastroenterol Suppl 2012; 107:S145.
    • 18. Siederdissen CHZ et al. Home-based Management of Refractory Ascites by Permanent Tunneled Peritoneal Catheter is an Effective Replacement for Recurrent Large Volume Paracentesis. EASL 2016. The International Liver Congress, Barcelona, Spain 13 - 17 April 2016, Poster SAT-006: Barcelona EASL.
    • 19. Semadeni GM, Gubler C, Nagy A, Manser C, Borovicka J, Semela D. Placement of a Permanent, Tunnelled Peritoneal Drainage Catheter (PleurX) for Refractory Malignant and Portal-hypertensive Ascites in a Multicentre Study. J Hepatol Suppl 2015; 62:S381.
  • No related research data.
  • Discovered through pilot similarity algorithms. Send us your feedback.

Share - Bookmark

Cite this article